focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 107.60
Bid: 107.60
Ask: 108.40
Change: -2.60 (-2.36%)
Spread: 0.80 (0.743%)
Open: 109.00
High: 109.00
Low: 106.60
Prev. Close: 110.20
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Syncona confident after Q1 market volatility

Tue, 16th Aug 2022 10:06

(Sharecast News) - Healthcare investor Syncona reported net assets of £1.33bn at the end of its first quarter on Tuesday, or 197.9p per share, up from £1.31bn and 194.4p per share at the end of March.

The FTSE 250 company said that made for a net asset value return of 1.8% in the three months ended 30 June, driven by the positive impact of foreign exchange across the portfolio and capital pool.

Its life science portfolio was valued at £561.8m, up from £524.9m, with a return of -0.2% in the quarter.

The share prices of Syncona's listed holdings were still being negatively impacted by market volatility, although the board said it remained "confident" in the fundamentals of its companies.

It added that the portfolio remained funded to deliver on upcoming clinical milestones in the 2023 financial year, with £38m deployed in the period and a capital base of £768.7m as at 30 June, down from £784.9m at the end of March.

The company said that capital base provided it with a strategic advantage, as it looked to fund "exciting" new opportunities while supporting its current portfolio.

"We are pleased with the continued progress across the Syncona portfolio during the quarter, with our companies delivering on a number of operational and clinical milestones," said Martin Murphy, chair and chief executive officer at Syncona Investment Management.

"Our strategic capital base remains a key competitive advantage, enabling us to continue to fund our companies through the current market conditions, with £38m of capital deployed in the quarter, and strongly positioning us to take advantage of exciting opportunities to found new Syncona companies."

Murphy said Syncona was founded with a long-term vision and approach to leverage its experience in managing life science companies through all market cycles.

"We are confident that we can navigate the current environment to deliver strong risk-adjusted returns for our shareholders and fulfil our purpose to extend and enhance human life."

At 0940 BST, shares in Syncona were down 0.2% at 199.2p.

Reporting by Josh White at Sharecast.com.

More News
31 Mar 2020 16:20

Director dealings: Syncona chair acquires shares

(Sharecast News) - Syncona revealed on Tuesday that chairperson Melanie Gee had acquired 26,500 ordinary shares in the FTSE 250-listed life sciences investor.

Read more
23 Mar 2020 09:36

Syncona flags delays to clinical programmes amid pandemic

(Sharecast News) - Syncona updated the market on its trading amid the Covid-19 coronavirus pandemic on Monday, reporting that since the start of the outbreak, it had taken measures to protect its employees, primarily centred around remote working, to help ensure it could continue to operate with as minimal disruption as possible.

Read more
23 Mar 2020 09:36

Syncona Expects Delays In Clinical Trials Due To Virus Disruption

Syncona Expects Delays In Clinical Trials Due To Virus Disruption

Read more
20 Mar 2020 15:57

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

DIRECTOR DEALINGS SUMMARY: Plus500 Team Spend GBP14 Million On Shares

Read more
5 Mar 2020 15:41

DIRECTOR DEALINGS SUMMARY: IAG Chair And Director Spend EUR1.2 Million

DIRECTOR DEALINGS SUMMARY: IAG Chair And Director Spend EUR1.2 Million

Read more
24 Feb 2020 12:28

Monday broker round-up

(Sharecast News) - Rentokil: Jefferies upgrades to buy with a target price of 620p.

Read more
12 Feb 2020 15:35

Syncona Investee Presents Positive Data For Fabry, Gaucher Studies

Syncona Investee Presents Positive Data For Fabry, Gaucher Studies

Read more
7 Feb 2020 14:37

Syncona Investee Freeline Reports Positive Data From FLT180a Trial

Syncona Investee Freeline Reports Positive Data From FLT180a Trial

Read more
4 Feb 2020 11:33

Syncona pleased at end of 'productive' quarter

(Sharecast News) - Healthcare investment company Syncona updated the market on the quarter ended 31 December on Tuesday, reporting that its had expanded, invested in and advanced its portfolio in the period.

Read more
4 Feb 2020 10:51

Syncona Net Assets Rise Slightly In "Productive" Third Quarter

Syncona Net Assets Rise Slightly In "Productive" Third Quarter

Read more
30 Jan 2020 16:34

Syncona, Arix Note New Data From Autolus Trial Of AUTO3 Cell Therapy

Syncona, Arix Note New Data From Autolus Trial Of AUTO3 Cell Therapy

Read more
23 Jan 2020 09:00

Syncona, Arix Note Pricing Of Public Offering By Autolus Therapeutics

Syncona, Arix Note Pricing Of Public Offering By Autolus Therapeutics

Read more
23 Jan 2020 08:14

Syncona puts $15m into Autolus US offering

(Sharecast News) - Healthcare investment company Syncona announced on Thursday that its portfolio company, Autolus Therapeutics, had confirmed the pricing of its underwritten public offering in the United States.

Read more
19 Dec 2019 08:58

Syncona Commits USD80 Million Investment Into Freeline Therapeutics

Syncona Commits USD80 Million Investment Into Freeline Therapeutics

Read more
19 Dec 2019 07:53

Syncona commits $80m to Freeline

(Sharecast News) - Healthcare company Syncona said it had made an $80m (£61.1m) funding commitment to biotech company Freeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.